The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Amryt Pharma plc | Common | 03217L106 | 28,824 | 2,668,843 | SH | SOLE | 2,668,843 | 0 | 0 | ||
Dyne Therapeutics, Inc. | Common | 26818M108 | 58,871 | 4,951,303 | SH | SOLE | 4,951,303 | 0 | 0 | ||
Entrada Therapeutics, Inc. | Common | 29384C108 | 75,769 | 4,425,784 | SH | SOLE | 4,425,784 | 0 | 0 | ||
Harpoon Therapeutics, Inc. | Common | 41358P106 | 23,642 | 3,131,388 | SH | SOLE | 3,131,388 | 0 | 0 | ||
iTeos Therapeutics, Inc. | Common | 46565G104 | 134,347 | 2,885,470 | SH | SOLE | 2,885,470 | 0 | 0 | ||
Oncorus, Inc. | Common | 68236R103 | 15,017 | 2,849,464 | SH | SOLE | 2,849,464 | 0 | 0 | ||
Repare Therapeutics, Inc. | Common | 760273102 | 47,297 | 2,242,636 | SH | SOLE | 2,242,636 | 0 | 0 | ||
Rhythm Pharmaceuticals, Inc. | Common | 76243J105 | 9,074 | 909,258 | SH | SOLE | 909,258 | 0 | 0 | ||
TCR2 Therapeutics, Inc. | Common | 87808K106 | 18,877 | 4,050,865 | SH | SOLE | 4,050,865 | 0 | 0 | ||
Werewolf Therapeutics, Inc. | Common | 95075A107 | 51,024 | 4,284,172 | SH | SOLE | 4,284,172 | 0 | 0 |